Navigation Links
Simultaneous Screening of 23 Drugs of Abuse in Oral Fluid Using an LC/MS/MS Method

Purpose

Researchers and forensic agencies that test samples or screen post mortem patient specimens for drugs of abuse currently employ immuno- or colourimetric assays. These assays suffer from a number of limitations:

They lack specificity.

They are not as commonly available for novel sample matrices such as saliva as they are for urine or serum samples.

They can be relatively costly due to the high volume of reagents used.

They are not commercially available for many significant drugs and their metabolites.

In addition, with conventional approaches, testing for drugs of abuse is done separately for each of several classes of compounds (e.g. opiates, benzodiazepines, etc.), which requires time-consuming multiple assays. To screen for a portfolio of drugs from different compound classes, it is often necessary to perform repeat analysis on indvidual samples.

Overview

This application note describes a novel LC/MS/MS research method for the simultaneous screening of 23 drugs of abuse from extracted oral fluid samples. This method provides equal or better sensitivity than traditional immunoassays, while also being more specific, more cost effective, and less time consuming.

Key Features

Sensitive and selective Multiple Reaction Monitoring (MRM) scan function provides linear quantitative analysis with wide dynamic range.

The patented LINAC collision cell within the Applied Biosystems/MDS SCIEX API 3000TM Mass Spectrometer increases the number of compounds that can be analyzed simultaneously, without loss of sensitivity or increased LC separation.

The quantitative facility of the Applied Biosystems/MDS SCIEX Analyst Software organizes and displays results for quick interpretation.

Results and Discussion

Calibration samples at or below current established cut-off levels were provided by Leeds Teaching Hospitals NHS Trust. The following data were generated from these calibration samples as well as patient samples kindly provided by Leeds Teaching Hospitals NHS Trust

Comparison with Current Methods

The following figures summarize the ability of the method to detect concentrations of the drugs of abuse described earlier at levels at or significantly below current established cut-off levels.

Fig. 1 shows a selection of opiates at 1 ng/ml in an oral fluid matrix. This is equivalent to approximately 10 times less than the current cut-off level.*

Figure 2 shows a range of benzodiazepines at 1 ng/ml in oral fluid matrix. This is equivalent to the current established cut off level.*

Multiple Compound Screening

As the method presented in this research study allows the screening of multiple compounds from various classes, it is possible to detect the presence of abused drugs in the presence of prescribed drugs. Figure 4 shows a patient sample with a large signal for methadone. However, smaller signals for morphine, codeine and 6-monoacetyl morphine can also be seen at levels above the cut-off.* The detection of 6-monoacetyl morphine is of particular significance, as it is a primary product from the metabolism of heroin.

Multi-compound screening also makes it possible to look at various drug metabolites. This gives further credence to suspected positive results by monitoring for the major metabolite. Figure 5 shows an actual patient sample, once again with a high methadone result. In this case, however, the sample also shows positive results for cocaine and for benzoylecgonine, a cocaine metabolite.

Another potential application for multi-compound screening is for determining whether or not a sample has been adulterated. For example, screening for methadone metabolites could establish if methadone had actually been taken or merely added to the sample prior to analysis.

Interpretation of Results Using the Analyst software, numerical results can be generated and results tables can be customized for easy interpretation and use. A typical results table, generated using a single point calibrator at the cut-off level, is shown in Figure 6. This table provides the analyst with immediate information as to whether the levels detected in the samples are above or below the accepted cut-off levels.*

* Refers to cut-off levels at time of going to press.

Conclusions

The LC/MS/MS method described here provides a rapid, simple and reliable test to detect 23 drugs of abuse in oral fluid. Based on the results of this study:

This method has potential as a fully quantitative testing method in research and forensic applications.

The method can be used to ascertain whether the detected level is above or below an established cut-off value, giving a simple yes/no test in the style of commercially available immunoassay systems.

Due its high sensitivity, the method has the potential to minimize sample preparation, in some cases, even to the point of direct sample injection.

Application of this method is further simplified by using the Analyst software to customize the presentation of results, allowing only relevant information to be displayed for rapid interpretation and use.

Acknowledgements

Applied Biosystems/MDS SCIEX acknowledges Stephen Lock, Daniel Blake and Michael Baynham, and our collaborator Keith Allen from Leeds Teaching Hospitals NHS Trust, UK for providing the method, samples and data for this application note.


'"/>

Source:


Page: All 1 2 3 4

Related biology technology :

1. Simultaneous Detection of 8 Cytokines in Mouse or Human Sera
2. Simultaneous Determination of Residues of Approximately 100 Pesticides and Metabolites in Fruit and Vegetables by LC/MS/MS
3. Simultaneously characterizing and quantifying chloramphenicol and its metabolite using LC/MS/MS
4. Simultaneous Detection of CYP3A4, CYP2D6 and CYP2C9 Metabolites with a Single, Sensitive, LC/MS/MS Method
5. Innovative Tissue Array Technology for High-Throughput Screening of Gene Expression
6. Screening of Beer-Spoilage Bacteria Using the LightCycler PCR Workflow System
7. LightCycler foodproof Beer Screening Kit
8. Development of a Multiplex Bead-Based Assay for Antibody Screening of a Nonhuman Primate Colony on the Bio-Plex System
9. Screening for potential beta 2-adrenergic receptor antagonists using CypHer5E and IN Cell Analyzer 1000
10. Screening for β2-adrenergic receptor agonists using the pH-sensitive dye,CypHer5, and the IN Cell Analyzer 3000
11. A Mix-and-Read Cell-Based Assay for Hybridoma Screening Using the FMAT 8100 HTS System
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Simultaneous Screening Drugs Abuse Oral Fluid Using Method

(Date:3/5/2015)... Plant disease specialists from around the ... Annual Meeting of The American Phytopathological Society. Details ... now at APSnet.org/meet . , The Preliminary Daily ... be held August 1-5, 2015 in Pasadena, California, U.S.A. ... Workshops, and committee meetings, all carefully balanced to deliver ...
(Date:3/5/2015)... Bi-Biomics today announced a discovery made ... The improvement in histological quality provided the detail ... all daughter cells. , After processing with Ultralight ... at 1000-1600x using light microscopy. Phylogenetic and ... daughter cells displayed predominant binary features --- one ...
(Date:3/5/2015)... TORONTO , March 5, 2015 /PRNewswire/ - Aptose ... developing new therapeutics and molecular diagnostics that target the ... G. Rice , Ph.D., Chairman, President and Chief Executive ... Conference on Tuesday, March 10 th at 9:30 ... Laguna Niguel, CA. Dr. Rice will provide ...
(Date:3/5/2015)... DUBLIN , Mar. 05, 2015 Research and ... addition of the "Mature Biotech Outlook 2015: New ... to their offering. All biotech companies ... Celgene (CELG), in past year, have given a positive ... These companies have been able to select therapy/niche indication ...
Breaking Biology Technology:American Phytopathological Society Announces Annual Meeting Daily Schedule 2Aptose Biosciences to Present at the 27th Annual ROTH Conference 2Aptose Biosciences to Present at the 27th Annual ROTH Conference 3Mature Biotech Outlook 2015: New Therapy Ventures Pave the Way for Success 2Mature Biotech Outlook 2015: New Therapy Ventures Pave the Way for Success 3
... Thrombosis, Low MACE Rates Out to ... ABBOTT PARK, Ill., March 13 Data published,today ... trial of a,fully bioabsorbable drug eluting stent for the ... clinically driven target,lesion revascularizations (retreatment of a diseased lesion), ...
... 13 Nile Therapeutics,Inc. (OTC Bulletin Board: NILT), ... results for 2007. Participants may access the archived,webcast ... section of,Nile,s website at http://www.nilethera.com . The ... the next quarterly conference call., For the ...
... FAIRFIELD, New Jersey, March 13 Unigene,Laboratories, ... not issue, authorize,or approve the press release ... was released yesterday. Pursuant to the Company,s,policies ... validate or,otherwise comment on reports issued by ...
Cached Biology Technology:The Lancet Publishes Results From World's First Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent 2The Lancet Publishes Results From World's First Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent 3The Lancet Publishes Results From World's First Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent 4Nile Therapeutics Reports 2007 Fourth Quarter and Full Year Financial Results 2Nile Therapeutics Reports 2007 Fourth Quarter and Full Year Financial Results 3Unigene Restates Policy on Analyst Reports 2
(Date:2/5/2015)... --NXT-ID, Inc. (NASDAQ: NXTD and NXTDW) ... on the growing mobile commerce market, announces the launch ... part of its 2015 marketing and branding initiatives for ... consumer website for Wocketwallet.com earlier this month. ... "Our new corporate website naturally showcases our premiere consumer ...
(Date:2/5/2015)... Jan. 30, 2015  It is gratifying to see ... potential for genomic science as a means to better ... and treatment.  I was honored to participate in today,s ... medicine program. Since the 1980s my ... genomics—from the first sequenced genome of a free living ...
(Date:1/22/2015)... Fla. , Jan. 13, 2015  Today, FreeWavz ... technology, launched its crowdfunding campaign on Fundable, ... the build of production capacity to meet customer ... Photo - http://photos.prnewswire.com/prnh/20150113/168790 ...
Breaking Biology News(10 mins):NXT-ID, Inc. Launches New Corporate Website As Part Of Ongoing 2015 Branding Initiatives For Wocket Smart Wallet 2NXT-ID, Inc. Launches New Corporate Website As Part Of Ongoing 2015 Branding Initiatives For Wocket Smart Wallet 3J. Craig Venter, Ph.D., Co-Founder and CEO, Human Longevity, Inc. (HLI) Participates in White House Precision Medicine Event 2FreeWavz Launches on Fundable to Drive Speed-to-Market in 2015 2
... journal Proceedings of the National Academy of Sciences , ... key player in regulating chromatin in yeast and humans. ... and a scientist at The Centre for Molecular Medicine and ... a dynamic DNA-protein complex, is involved in numerous cellular processes ...
... Ground-breaking discoveries by Michigan State University researchers could ... commercial colonies. The MSU researchers for the first ... that help channel sodium ions through cell membranes of ... frog eggs, also found that these proteins react to ...
... The castration of pigs prevents the "boar taint" smell in ... However in practice this can be very different. Now, for ... the conditions of castration on European pigs. The main conclusion ... is that these animals are castrated directly by the livestock ...
Cached Biology News:MSU research may lead to new ways to control honeybee parasite 277 percent of European pigs are castrated without anesthetic 2
Coating : Poly-D-Lysine ,Surface : ECM/attachment factors ,Surface area : 9.6 cm2 ,Dim nominal : 35 mm x 10 mm ,Vol working : 2.5-3.0 ml ...
...
BD BioCoat Collagen IV 35 mm Culture Dishes, tissue-culture treated polystyrene with a uniform application of mouse collagen type IV....
... primers are designed for sequencing inserts cloned ... T7, or T3 RNA polymerase promoters, or ... supplied at a concentration of 0.1 µg/µl ... in DNA sequencing reactions using SequiTherm™ EXCEL™ ...
Biology Products: